Comparative risk of the incident cancer between histamine-2 receptor antagonists (Risk of cancer between H2RAs)

19/04/2021
23/04/2024
EU PAS number:
EUPAS38902
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

H2RACancerRisk_Protocol_V0.5

English (679.44 KB - PDF) View document
Updated protocol

H2RACancerRisk_Protocol_V0.5.1

First published: 22/02/2024
English (691.94 KB - PDF) View document
Study results
Study report
Other information